VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021

Jun 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-06-01

Reporting Person: MCGLYNN MARGARET G (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-01	Common Stock	D	699	—	Disposed	1099	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-01	Deferred Stock Units	$	A	699	Acquired		Common Stock (699)	Direct

Footnotes

F1: Upon the vesting of restricted stock units granted to Ms. McGlynn on June 1, 2020, Ms. McGlynn deferred the receipt of 699 shares of common stock and received instead 699 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 699 shares of common stock in exchange for an equal number of deferred stock units.

F2: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McGlynn's disability or death.